CA-LEVITASBIO
7.4.2022 15:17:04 CEST | Business Wire | Press release
LevitasBio, Inc. today unveiled the LeviCell™ EOS System, their next generation solution for cell separation and enrichment, featuring higher throughput and simultaneous targeted selection of viable cells. Utilizing field proven Levitation Technology, researchers can now effectively scale their experiments up to 16x and process up to 40 million cells per run. The LeviCell EOS System debuts, along with new LeviPrep and LeviSelect product lines for tissue dissociation and targeted cellular selection, at the 2022 American Association for Cancer Research General Meeting held April 8-13 in New Orleans, Louisiana.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220407005408/en/
Unprecedented Sample Throughput and Scalability
LevitasBio first revolutionized sample preparation in 2020 with the launch of the LeviCell System, which introduced researchers to a gentle, fast, and unbiased method to separate and enrich cells of interest via magnetic levitation. Less than two years later, LevitasBio has addressed researchers’ oft stated desire for scalability, both in the quantity of samples and cells that can be levitated and accessed. The new LeviCell EOS system increases sample throughput by four-fold and enables up to four LeviCell EOS modules to be interconnected and independently controlled, increasing total scalability by 16x. Researchers can now accelerate their discoveries with unprecedented sample processing power and insights.
A New Era in Sample Processing
The LeviCell EOS system introduces several new features that enhance unbiased sample processing to optimize the study of natural biology. First is an embedded thermal control system, which allow users to select from a range of pre-defined temperatures, ensuring samples are processed at ideal temperatures to maintain cellular states.
Additionally, an advanced, fully reticulated imaging system enables powerful, real-time sample characterization analytics during processing. Important insights such as fractionation, cell counts, viability assessment, and quality measurements, can be reviewed real-time, empowering researchers to make informed decisions on how to best utilize their enriched samples in downstream studies.
Finally, the LeviCell EOS system delivers unprecedented flexibility with a modular and interchangeable EOS Magnetic Core. A growing family of selectable core modules will enable a broad range of specifically optimized applications on a single platform.
“We are changing the landscape of how researchers conduct their experiments,” says Martin Pieprzyk, CEO of LevitasBio. “The new LeviCell EOS system paves the way for fully integrated approaches to sample processing and accurate characterization at scaled throughputs. This marks a profound shift in how scientists work with their samples.”
For more information, visit http://www.levitasbio.com/eos . For collaborations and business development, contact Paul Steinberg at steinberg@levitasbio.com .
About LevitasBio
LevitasBio has pioneered a new and powerful method of cellular enrichment and analysis. Utilizing proprietary Levitation Technology, our LeviCell platform can accurately and gently detect, quantify, enrich, and test cells. Our unbiased, label-free method can detect cell type and state with minimal time and handling, and has been adopted across a broad range of critical applications, including single cell multi-omics, CRISPR, and cell line development.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220407005408/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom